Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s share price dropped 6.3% on Friday . The stock traded as low as $2.56 and last traded at $2.67. Approximately 1,376,097 shares were traded during trading, an increase of 89% from the average daily volume of 727,249 shares. The stock had previously closed at $2.85.

CNAT has been the subject of several recent research reports. Oppenheimer set a $10.00 price target on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 6th. SunTrust Banks dropped their price target on Conatus Pharmaceuticals to $12.00 and set a “buy” rating for the company in a research report on Thursday, December 6th. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. ValuEngine cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 11th. Finally, Roth Capital restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Wednesday, February 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Conatus Pharmaceuticals has an average rating of “Hold” and a consensus price target of $7.10.

The firm has a market capitalization of $80.80 million, a PE ratio of -4.53 and a beta of 3.36.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million for the quarter, compared to analysts’ expectations of $8.63 million. Equities research analysts forecast that Conatus Pharmaceuticals Inc will post -0.38 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in Conatus Pharmaceuticals by 13.4% in the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after acquiring an additional 191,287 shares during the last quarter. Sofinnova Investments Inc. boosted its holdings in Conatus Pharmaceuticals by 18.4% in the fourth quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 99,282 shares during the last quarter. Artal Group S.A. acquired a new position in Conatus Pharmaceuticals in the third quarter valued at $2,900,000. Two Sigma Investments LP boosted its holdings in Conatus Pharmaceuticals by 761.1% in the fourth quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after acquiring an additional 221,044 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Conatus Pharmaceuticals by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 33,827 shares during the last quarter. Institutional investors and hedge funds own 27.41% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.mareainformativa.com/news/2019/03/17/conatus-pharmaceuticals-cnat-trading-down-6-3.html.

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Recommended Story: What are economic reports?

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.